Introduction
There are multiple forms of human immunodeficiency virus type 1 (HIV-1) which coexist within an infected host (Wain-Hobson, 1989 ). The variation between the different forms of the virus within a single host is less than that which exists between independent isolates of the virus . It is not randomly distributed throughout the viral genome but is concentrated into discrete regions within the external envelope glycoprotein (gp 120) gene (Willey et al., 1986; Modrow et al., 1987) and includes insertions or deletions of three to five residues, or substitutions, leading to a change in a single amino acid. Since these variable regions contain N-glycosylation sites (motif: Asp-X-Ser or Thr), the number and position of the carbohydrate moieties also differ between forms of the virus within a single host (Hahn et al., 1986; Simmonds et al., 1990 Simmonds et al., , 1991 . AU the N-glycosylation sites within the external envelope glycoprotein of HIV-1 have been shown to be utilized (Leonard et al., 1990) . Over time, HIV changes within an individual host to become more pathogenic, and also as neutralization-resistant variants emerge (Albert et al., 1990; Montefiori et al., 1991; Wolfs et al., 1991) .
Epitopes within the protein backbone of gp 120 which include a glycosylation site may become cryptic, for T cells (Botarelli et al., 1991) , or sequestered from antibody (Davis et al., 1990b) , when the carbohydrate moiety is attached. Davis et al. (1990b) suggested further that antibodies, whose binding to the different forms of the virus may vary by virtue of the number and position of the carbohydrate molecules within the variable regions, can shift the dynamic equilibrium between variants within a single host. Under these circumstances, it will be important to establish whether antibodies to the variable N-glycosylated regions are induced by candidate vaccines.
The concept of cryptic or sequestered epitopes was developed with evidence obtained with T cells raised to recombinant proteins (Botarelli et al., 1991) or with antipeptide sera (Davis et al., 1990b) . If such epitopes are to play a role in the pathogenesis of HIV-1 infection, such T cells and antibodies will have to be demonstrated in infected hosts. Since the relevant antibodies are induced by the most variable regions, such studies will require peptides whose sequences are identical to those of the infecting virus. Several groups of workers have documented the epitopes of the envelope glycoproteins recognized by patients' sera (Goudsmit et al., 1988; Mathiesen et al., 1989; Davis et al., 1990 a, b; Neurath et al., 1990; Horal et al., 1991) . However only one of these (Goudsmit et al., 1988) examined sera from chimpanzees, where the infecting virus and the peptides were homologous. In the others, the strain of virus infecting the patient was unknown, but presumed to be heterologous. In the present study, we have used a complete series of overlapping peptides with the HIV-1 SF2 amino acid sequence and sera from chimpanzees infected with the homologous virus. Sera from baboons injected with SF2 recombinant proteins were also used to determine whether vaccination induces antibodies to the variable N-glycosylated regions.
It is probable that under conditions of natural transmission, the inoculum will be a mixture of related viruses, and a vaccine strategy must take this factor into account. Currently, successful vaccination has correlated with antibodies to a single neutralizing region within the V3/GPGR loop (Berman et al., 1990; Girard et al., 1991) , but the level of protection has been very low and seen only with challenge inocula of approximately 10 IDs0. If antibodies could be induced to multiple neutralizing epitopes, it might then be expected that the number of viruses present in an inoculum which could escape from neutralization would be lower so that higher levels of protection would be observed. However, escape may not be associated with simple mutations within the neutralizing epitope, since Nara et al. (1990) found that in an unsuccessful vaccine study the property of neutralization resistance, as assayed with a monoclonal antibody (MAb), emerged without any change in the amino acids that bound the antibody. In the present study, the specificity of antibodies, as judged by their binding to a homologous series of overlapping peptides representing the whole of the external envelope glycoprotein, is determined for candidate vaccines injected into baboons. The presence of peaks of antibody binding, correlating with peptides which previously have been shown to induce neutralizing antibodies, demonstrates that the potential exists for the induction of a spectrum of such antibodies in a vaccinee. Provided that the titres of these antibodies are high enough, the presence of a range of specificities within a vaccinated host should reduce the number of viruses within an inoculum which are able to escape neutralization, as well as inhibiting the emergence of variants.
Methods
Peptides. A complete series of overlapping, synthetic peptides representing the envelope glycoproteins of HIV-1 SF2 was used. The N and C termini of the individual 15-mer peptides are given by the formulae y = 10x -9 and y" = 10x + 5 where y and y' are respectively the N and C termini, and x is the peptide number (Davis et aL, 1990a, b) .
Solid phase antipeptide radioimmunoassay. Peptides were used as the solid phase in a radioimmunoassay as previously described (Davis et al., 1990a) with the following modifications: irradiated, rigid ELISA plates (Dynatech) were used and residual radioactivity was counted after it had been removed from the solid phase with 0.1 M-sodium hydroxide.
Epitope mapping with hexamers and octamers. Peptides were synthesized on polyacrylic acid-coated polyethylene rods by the 9' ttuorenylmethoxycarbonyl-polyamide mode of synthesis as previously described (Davis et al., 1990b) .
Absorption/elution/reabsorption/amplification assay. This technique has been modified from that described by Tribbick et al. (1991) . Peptides synthesized on rods were incubated in a 1 : 50 dilution of serum in PBS with 0.05 % Tween 20 in a wet box on a rocking tray at 4 °C overnight. They were then washed (4 x I0 min) in diluent and incubated in Universal buffer (1 M-citric acid, 1 M-phosphoric acid, 1 Msodium hydroxide, 0.1 M-hydrochloric acid and 57 mM-orthoboric acid, pH 2.5) for 10 rain at room temperature. Antibody bound to the pins is thus eluted into the wells of a 96-well plate. Sufficient 0.1 M-sodium hydroxide was then added to each well so as to return the pH to 7, and was followed by PBS containing 0.05 % Tween 20 and 2 % bovine serum albumin to minimize antibody binding to the microtitre plate. The peptides on their rods were cleaned by sonication as previously described (Davis et al., 1990b ). The clean peptides were then reincubated in their corresponding wells at 4 °C overnight, washed and transferred to wells containing alkaline phosphatase-conjugated antihuman immunoglobulin before incubating at room temperature for 90 min on a rocking table. The binding of enzyme-labelled antibody to the rods was detected using the substrate and amplification system provided with AMPAK (Novo Biolabs) according to the manufacturer's directions. Colour development was monitored visually and the reaction was stopped to give optimal discrimination between positive and negative wells whilst retaining low backgrounds.
Sera. Sera were obtained from five chimpanzees, infected with HIV-1 SF2 between October 1984 and July 1986 (Morrow et al., 1989) . Chimpanzees X88, X97, X117 and X120 were injected intravenously or intraperitoneally with HIV-1 SF2, and X123 with HIV-I SF2 which had been derived from a molecular clone (Castro et al., 1989) . Inocula were 5 to 20 ml and contained 104 to 105 infectious viruses per ml. Chimpanzees X88 and X120 were subsequently superinfected with HIV-1 SF170 32 months after their first inoculation with SF2. The animals were bled in September or October 1990. Sera from infected animals were treated with Triton X-100 (final concentration 1%) to eliminate infectious virus.
Baboons, numbers 2951, 2952, 2953, 2957, 2958 and 2964, were injected intramuscularly at 1, 2, 3, 4, 6, 12, 13 and 17 months with HIV-1 SF2 recombinant proteins emulsified in incomplete Freund's adjuvant supplemented with 250 Ixg muramyl tripeptide and bled 2 weeks after their eighth injection .
Results

15-mer peptides of gp 120 recognized by antibodies in chimpanzee sera
The presence of peptides in solution was confirmed by scanning between 180 and 300 nm in a u.v. spectrophotometer. The availability of peptides to bind antibody was confirmed by using sera raised in rats to each peptide (Davis et al., 1990a, b) in control plates run in parallel with experimental sera (data not shown). Peptides representing the variable regions of gpl20 were most frequently recognized by antibodies in sera from chimpanzees infected with HIV. The pattern of antibody binding to the variable regions was different for each chimpanzee. Thus, high levels of antibody binding to the V3 peptides were seen for sera from three chimpanzees: X117 had high levels only to the V3 region but the others also had antibodies to the V1 and V2 regions (X123) or the V1 region (X120). Chimpanzee X97 had high levels of antibodies to the V1 region only and X88 had low levels of antibodies to all the peptides examined (Fig. 1) .
Sera from some chimpanzees also bound to peptides representing conserved sequences, with high levels of antibodies only being observed to peptides representing amino acids 81 to 115 (X97 and Xl17) and 501 to 515 (X120). 
Hexamer peptides of gp l20 recognized by antibodies in chimpanzee sera
Our experience using peptides on pins is that epitopes can be discriminated very well when hyperimmune sera (Davis et al., 1990b) or MAbs are used (D. M. Stephens, unpublished observation) but that high backgrounds are seen with clinical samples. In efforts to reduce these backgrounds we found that no activity could be demonstrated when the acid-ehtion technique of Tribbick et al. (1991) was used with clinical sera but that antibodies which reabsorbed to the peptides could be detected when, in addition, an amplification system was used. Peptides in regions where glycosylation sites vary in number and position were mapped in detail using hexamers (Fig. 2) . Since the reaction was stopped to optimize discrimination between positive and negative wells, comparisons could be made only within a single serum. The peptide showing the highest binding of antibody could be either immediately N-terminal, Cterminal or remote from glycosylation sites.
15-mer peptides of gp41 recognized by antibodies in chimpanzee sera
The pattern of antibody binding to peptides representing the transmembrane protein, gp41, also varied between chimpanzees. Two chimpanzees (Xl17 and X120) had antibodies at high levels to peptide env61 (601 to 615). env86 (851 to 863) for chimpanzee X120. Chimpanzee X97 had the highest level of antibodies to peptide env80 (791 to 805), with peptide env69 (681 to 695) showing the second highest level. Chimpanzees X88 and X123 had low levels of antibodies to all peptides studied (Fig. 3) .
Octamer peptides used to identify epitopes within the immunodominant regions
Chimpanzee sera showed very little activity against hexamers representing env32 (311 to 325) and env61 (601 to 615), the two immunodominant epitopes of the external and transmembrane envelope glycoproteins respectively. This failure may be a technical limitation since other workers have previously indicated that the putative fl-turn, GPGR sequence and its flanking amino acids and the region between the two cysteine residues (605 and 611) are the most antigenic sites. Increasing their length has been shown to improve the ability of peptides to bind antibodies, and would also permit both cysteines to be included in the env61 peptides. Octamer Env32 Env61 N-terminal amino acid peptides representing env32 and env61 were therefore synthesized on rods and used to bind antibodies from chimpanzee sera. Chimpanzee X117 showed antibodies to the octamer SIYIGPGR (Fig. 4) whereas chimpanzee X97, which showed low activities to the 15-mer peptide, also showed low levels of binding to the GPGR peptide. Antibodies in sera from chimpanzee Xll7 show the highest level of binding to octamer CSGKLICT which includes both cysteine residues, but X120 shows highest binding to the peptide GKLICTTA.
15-mer peptides of gpl20 recognized by antibodies in baboon sera
The pattern of antibody binding to peptides for sera of baboons injected with recombinant gpl20 was similar for each animal within the two groups, injected with either glycosylated or non-glycosylated gpl20 (Fig. 5) . For epitopes within the conserved regions of the molecule, three peaks of binding activity were present in sera from animals in both groups: peptides envl2 (111 to 125), env28 (271 to 285) and env50 (491 to 505). Sera from baboons injected with glycosylated material had additional peaks represented by peptides env22 (211 to ( ) and Neurath et al. (1990 . Shaded areas represent neutralizing epitopes and hatched areas represent regions where there is disagreement between reports of neutralization. There is no evidence for a neutralizing epitope in the open areas.
225) and env44 (431 to 445) whereas those taken from animals injected with non-glycosylated material had extra peaks with peptides env9 (81 to 95), env38 (371 to 385) and env48 (471 to 485). Some differences between the response to the two immunogens are also seen with the pattern of antibody binding to the variable regions. Thus, sera from animals injected with glycosylated gpl20 showed high levels of antibody binding across the entire V1 and V2 regions, corresponding to peptides envl4 to env20, with the highest peak at peptide envl9 (181 to 195) and minor peaks at peptides envl4 (131 to 145) and envl6 (151 to 165). Sera from animals injected with non-glycosylated molecules showed distinct peaks of antibody binding with peptides representing the V1 and V2 regions, with the highest binding to peptides envl5 (141 to 155) and envl8 (171 to 185). Comparable high levels of antibody binding to peptides of the V3 region (env32 and env33) were seen with sera raised against both immunogens. Similarly, both immunogens gave low levels of binding with peptides representing the V4 region (env41 and env42) and moderate levels to the V5 region (env47).
Discussion
There is considerable variation in the amino acid sequence of the HIV-1 external envelope glycoprotein. This variation is not randomly distributed throughout the entire molecule, but is concentrated into five regions (Willey et al., 1986; Modrow et al., 1987) . These regions also include many N-glycosylation sites which also show variation in their number and position, not only between isolates of the virus from different patients but also between those separated over time from the same patient (Hahn et al., 1986; Simmonds et al., 1990 Simmonds et al., , 1991 . It has been suggested that carbohydrate molecules may mask epitopes (Davis et al., 1990b; BotareUi et al., 1991) within the external envelope glycoprotein of HIV-1. Furthermore, shifts in the position of the glycosylation sites may lead to the production of neutralization-resistant variants and represent one mechanism by which the virus can evade the host's immune response (Davis et at., 1990b) . This hypothesis requires that the host produces antibodies to those regions where the glycosylation sites are most variable, a requirement which has been demonstrated in the present communication.
The variability of the amino acid sequences is a problem which must be overcome if antibodies to these regions are to be detected with confidence. Previous work has shown that patients do have antibodies to the variable regions of heterologous viruses. In particular, they have high levels of antibodies to the second and third variable regions which can be demonstrated with 15-mer peptides representing the SF2 sequence (Davis et al., 1990b) or nonamers on rods with the BH10 sequence (Goudsmit et al., 1988) . In addition, the latter authors demonstrated antibodies to the V 1 region using patients' sera. The use of sera from eight chimpanzees which had been infected with homologous virus failed to demonstrate antibodies other than ones to the V3/GPGR region (Goudsmit et al., 1988) . In the present study antibodies have been detected to all the variable regions in the sera of chimpanzees infected with SF2 virus, the homologous strain whose sequence was used to synthesize the peptides.
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Examination of the amino acids that bind antibody, as determined by fine mapping with hexamer peptides, illustrates the range of possibilities of carbohydrate masking epitopes on the protein backbone. Thus, the peptide showing the highest level of antibody binding in Fig. 2(f) , NNNTRK, includes a glycosylation site. It can be reasonably expected that antibodies to this epitope would fail to bind to the glycosylated protein especially when it is recalled that antibodies raised against peptides representing this region could bind to non-glycosylated gpl20 but not to glycosylated proteins (Davis et al., 1990b) . However, the highest binding peptide depicted in Fig. 2 (/) is immediately C-terminal to the glycosylation site, and no interference with binding can be predicted. The further elaboration of this hypothesis will require the demonstration that antibodies to the glycosylated zones within the variable regions are involved in neutralization and/or in enhancing the uptake of the virus into cells with complement or immunoglobulin receptors and that the titre of a patient's antibodies to individual epitopes within these zones varies in synchrony with shifts in the glycosylation sites. This latter point will involve the collection of sera over a series of time points from the same patient and their examination using peptides whose sequences are those of the homologous virus and will have been determined using the polymerase chain reaction.
Assays with 15-mer peptides as a solid phase for radioimmunoassays (RIAs) and hexamers or octamers on pins to be used in ELISA can not be substituted one for another. Goudsmit et al. (1988) noted that the highly reactive epitope at the C terminus of gpl20 observed by Palker et al. (1987) was not detectable with nonamers. In the present study the reverse situation has been shown to be possible. Thus, antibodies could be detected in serum from chimpanzee Xl17 with hexamer peptides representing the V4 region but not with 15-mer peptides used as the solid phase in RIA. There are at least two possible factors which can influence the specific binding of antibodies to peptides. First, the antibody does not bind with equal energy to all the individual residues so that, in this sense, most epitopes are discontinuous although contained in a short, linear sequence of amino acids from the original immunogen. A linear epitope is then one in which the residues principally involved in binding antibody lie within a stretch of six to 15 amino acids of the immunogen's sequence. Second, the number of amino acids can also influence the conformation of the peptide so that the principal residues may not necessarily be in the correct spatial arrangement in both long and short peptides that otherwise include the same sequence. In this sense, all antibodies recognize conformational epitopes.
Antibodies to the immunodominant regions of gpl20 and gp41 could not be detected with hexamers in the present study. Octamers were required when the GPGR and CSGKLIC motifs were included. These results are in accord with those of Goudsmit et al. (1988) and Zwart et al. (1991) who showed that septamers or octamers were optimal for binding antibodies to peptides including the GPGR motif, although antibodies could bind to pentapeptides which did not include all four of these residues. Horal et al. (1991) detected antibodies with peptides representing the gp41 immunodominant epitope using hexamers, which could not contain both cysteines of the minimal essential epitope described by Gnann et al. (1987) . However, these latter authors investigated the effect on antibody binding of residues on only the Nterminal side of this minimal epitope, whereas Horal et al. (1991) and the present study demonstrated that the highest level of binding with some sera was to peptides which included residues on the C-terminal flank. Warren et al. (1990) used selected peptides of varying length, representing the HTLV IIIb amino acid sequence, to detect antibodies in chimpanzees infected with LAV, IIIb or SF2 virus strains. Their conclusion was that the epitopes which had been found to be immunodominant in human infection were not so in the chimpanzee, in as much as less than half of the infected chimpanzees had significant levels of antibodies to peptides 308 to 323 and 600 to 611, equivalent to peptides env31, env32 and env61 used in the present study. The results presented here indicate that although these peptides are not recognized by all infected chimpanzees, where antibodies are present they are at high levels. The discrepancy in the results may be explained by the absence of the complete GPGR motif from the V3 peptide of Warren et al. (1990) . Also, if sera from uninfected chimpanzees have high levels of antibodies to the gp41 motif, as is found with humans (Davis et al., 1990a) , their use as a baseline against which to measure levels of antibody in sera from infected animals may mean that differences fail to reach significance.
In contrast with the variability seen in chimpanzees, individual baboons gave more uniform patterns of antibody binding to peptides following injection with recombinant SF2 gpl20. Even more encouraging for a candidate vaccine is that a comparison of the peptides that bind the highest levels of antibodies and those which induce neutralizing antibodies in experimental animals (Chahn et al., 1986; Ho et al., 1987 Ho et al., , 1988 Neurath et al., 1990) shows a number of zones where both these properties coincide. These zones are present in both conserved and variable regions of the molecule. These observations open a number of lines of investigation for future development of HIV vaccines.
The current status of HIV vaccine development is that chimpanzees can be protected against low doses of homologous virus. Success has been associated with the presence of antibodies to a peptide representing the VD/GPGR loop (Berman et al., 1990) or with boosting the titre of neutralizing antibodies with VD/GPGR loop peptides (Girard et al., 1991) . Failure to protect chimpanzees, in other studies, has been followed by the emergence of variant viruses able to resist neutralization by a MAb that binds to the VD/GPGR loop (Nara et al., 1990). The next logical step appears to be an attempt to boost the level of antibodies to neutralizing epitopes in addition to the VD/GPGR loop. In animals with high levels of antibodies to two independent neutralizing epitopes, the emergence of variant viruses would require more than one mutation and protection would increase as a function of the product of the mutation rates. The V2 region is a likely candidate for a second neutralizing epitope since recent reports confirm that it contains a neutralizing epitope (Stephens et al., 1991) which may also be cross-neutralizing (Fung et al., 1991) .
Ultimately, a vaccine will be required which protects against heterologous challenge. If a vaccination strategy is envisaged where animals are primed with whole gpl20 and boosted with peptides representing neutralizing epitopes, then cross-protection might be expected from neutralizing antibodies raised against conserved regions of gpl20 which are also immunogenic in recombinant proteins. In the present study, both glycosylated and nonglycosylated material gave antibody binding peaks within amino acid sequences 111 to 125, 271 to 285 and 491 to 505 which coincided with neutralizing epitopes, although epitope 271 to 285 was considered not to be neutralizing by Ronco et al. (1991) and human antibodies, affinity-purified by using peptide 503 to 515, did not neutralize the virus (Palker et al., 1987) . Non-glycosylated gpl20 gives an additional peak at peptide 371 to 385 which has a neutralizing epitope (Neurath et al., 1990) . Current work with antibodies raised against the peptides used in this study will define more comprehensively the neutralizing epitopes within the C-terminal region (421 to 518) of gpl20.
